Eyes - All posts

Vision gains in early dry AMD stem cell transplant trial

An open-label phase 1/2a report in Cell Stem Cell covers the first six participants in the lowest-dose arm of a donor-derived RPE stem cell trial for geographic atrophy. Chart scores in the poorest-vision group rose on average at a 12-month visit, and the better-vision group showed a modest average gain at six months, but the cohort is too small and too early to treat as proof of efficacy or as standard care.